In summary, our preclinical data suggest that a bi-steric mTORC1-selective inhibition may be an effective approach for overcoming resistance to standard of care therapeutics in breast cancers, especially in ER+ tumors that harbor mutations that activate mTORC1 including PIK3CA and PTEN. Here, PIK3CA is linked to breast cancer.